RSV infects almost every child before they turn 2, and kills more than 100,000 infants worldwide each year. Machine learning ...

Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...

Medical risk-based approaches outperformed age-based strategies, even when vaccine prices were low, the study authors said.

Targeting vaccination programs for respiratory syncytial virus (RSV) to older adults with underlying health conditions is a cost-effective way to reduce disease, according to a new modelling study in ...

Vaccines for the Fall and Winter 2024–2025 season are now available. Generally, experts recommend COVID-19 and flu vaccines ...

British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles ...

With the flu season imminent, new COVID-19 and influenza vaccines are available. What’s new with the vaccines and when should ...

Most people experience mild RSV reinfections throughout their lifetime, particularly during respiratory virus season (November to March in Canada). People are at higher risk if they are older than 75 ...

Of the eligible infants, 897 (53.4%) were infected with RSV in the first year of life and 783 (46.6%) were not. Active ...

British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...

KIRKLAND, QC, Sept. 19, 2024 /CNW/ - Today, Pfizer Canada ULC announced that ABRYSVO™ has been selected as the publicly-funded vaccine for the prevention of Respiratory Syncytial Virus (RSV) in ...

RSV infections cause major illness, especially in infants and older adults, and rates of infection increase with age. There are now vaccines available to prevent disease caused by RSV in adults ...